| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045294653 |
| P356 | DOI | 10.1186/1471-2202-13-33 |
| P932 | PMC publication ID | 3352246 |
| P698 | PubMed publication ID | 22443187 |
| P5875 | ResearchGate publication ID | 221972001 |
| P2093 | author name string | Christian Hölscher | |
| Kerry Hunter | |||
| P2860 | cites work | Glucagon-like peptide-1 receptor is involved in learning and neuroprotection | Q28202403 |
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling | Q28574687 | ||
| Biology of incretins: GLP-1 and GIP | Q29617302 | ||
| GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. | Q34167980 | ||
| Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice | Q35180081 | ||
| Neurodegenerative disorders associated with diabetes mellitus | Q35791191 | ||
| Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease | Q36172658 | ||
| Liraglutide: a new treatment for type 2 diabetes | Q37431559 | ||
| Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. | Q37718840 | ||
| Lixisenatide for type 2 diabetes mellitus | Q37851499 | ||
| Glucose tolerance status and risk of dementia in the community: the Hisayama study | Q43584777 | ||
| Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans | Q44178339 | ||
| Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. | Q45925400 | ||
| Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice | Q46324379 | ||
| Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. | Q48575219 | ||
| The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. | Q51011184 | ||
| Val8-glucagon-like peptide-1 protects against Aβ1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats. | Q51040221 | ||
| Hyperinsulinemia and risk of Alzheimer disease. | Q51526824 | ||
| Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites | Q70905833 | ||
| Entry of exendin-4 into brain is rapid but may be limited at high doses | Q73107463 | ||
| Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain | Q83396445 | ||
| The effect of exenatide re-exposure on safety and efficacy | Q84167596 | ||
| P275 | copyright license | Creative Commons Attribution 2.0 Generic | Q19125117 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | blood–brain barrier | Q221694 |
| neurogenesis | Q1456827 | ||
| liraglutide | Q2526479 | ||
| P304 | page(s) | 33 | |
| P577 | publication date | 2012-03-23 | |
| P1433 | published in | BMC Neuroscience | Q15766477 |
| P1476 | title | Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis | |
| P478 | volume | 13 |
| Q44476616 | (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice |
| Q39266481 | A New Treatment Strategy for Parkinson's Disease Through the Gut-Brain Axis: The Glucagon-like Peptide-1 Receptor Pathway |
| Q51786227 | A New Treatment Strategy for Parkinson's Disease through the Gut-Brain Axis: The Glucagon-Like Peptide-1 Receptor Pathway. |
| Q38739185 | A Novel Bioresorbable Device as a Controlled Release System for Protecting Cells from Oxidative Stress from Alzheimer's Disease. |
| Q41070874 | A Novel GLP1 Receptor Interacting Protein ATP6ap2 Regulates Insulin Secretion in Pancreatic Beta Cells |
| Q47736265 | A Vitamin B12 Conjugate of Exendin-4 Improves Glucose Tolerance Without Associated Nausea or Hypophagia in Rodents. |
| Q90321185 | A novel mouse model of glucagon-like peptide-1 receptor expression: A look at the brain |
| Q38073138 | A review: treatment of Alzheimer's disease discovered in repurposed agents |
| Q99404602 | Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function |
| Q28086892 | Alzheimer's disease and type 2 diabetes via chronic inflammatory mechanisms |
| Q26750746 | Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control |
| Q48209483 | Beneficial effects of liraglutide (GLP1 analog) in the hippocampal inflammation. |
| Q35991683 | Brain GLP-1 and insulin sensitivity |
| Q39170234 | Brain injury with diabetes mellitus: evidence, mechanisms and treatment implications |
| Q27012801 | Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs |
| Q90183205 | Central Glucagon-like Peptide-1 Receptor Signaling via Brainstem Catecholamine Neurons Counteracts Hypertension in Spontaneously Hypertensive Rats |
| Q35106896 | Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models |
| Q34639384 | Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model |
| Q48178356 | DPP4 Inhibitors Can Be a Drug of Choice for Type 3 Diabetes: A Mini Review |
| Q35213829 | Deterioration of plasticity and metabolic homeostasis in the brain of the UCD-T2DM rat model of naturally occurring type-2 diabetes |
| Q33959406 | Differences in acute anorectic effects of long-acting GLP-1 receptor agonists in rats. |
| Q27024122 | Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease |
| Q52151966 | Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. |
| Q48059966 | Effect of Liraglutide on Corneal Kindling Epilepsy Induced Depression and Cognitive Impairment in Mice |
| Q92042716 | Effects of GLP-1 Receptor Activation on a Pentylenetetrazole-Kindling Rat Model |
| Q47899237 | Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling |
| Q58091552 | Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys |
| Q47811538 | Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons |
| Q48877643 | Effects of liraglutide in hypothalamic arcuate nucleus of obese mice |
| Q35306023 | Elucidating molecular phenotypes caused by the SORL1 Alzheimer's disease genetic risk factor using human induced pluripotent stem cells |
| Q48106516 | Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System. |
| Q48164658 | Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial |
| Q37406399 | Exendin-4 antagonizes Aβ1-42-induced attenuation of spatial learning and memory ability |
| Q37179909 | Exendin-4 induced glucagon-like peptide-1 receptor activation reverses behavioral impairments of mild traumatic brain injury in mice |
| Q48422656 | Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes |
| Q34745109 | Expression and distribution of glucagon-like peptide-1 receptor mRNA, protein and binding in the male nonhuman primate (Macaca mulatta) brain. |
| Q38194069 | Extra-pancreatic effects of incretin-based therapies |
| Q50296503 | Factors that influence adult neurogenesis as potential therapy. |
| Q28651569 | GLP-1 improves neuropathology after murine cold lesion brain trauma |
| Q36406821 | GLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond. |
| Q34511743 | GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-cont |
| Q91895259 | GLP-1 secretion in acute ischemic stroke: association with functional outcome and comparison with healthy individuals |
| Q60044940 | GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data |
| Q41700809 | Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. |
| Q37421211 | Glucagon-Like Peptide-1 Analog, Liraglutide, Delays Onset of Experimental Autoimmune Encephalitis in Lewis Rats |
| Q37246805 | Glucagon-Like Peptide-1 Excites Firing and Increases GABAergic Miniature Postsynaptic Currents (mPSCs) in Gonadotropin-Releasing Hormone (GnRH) Neurons of the Male Mice via Activation of Nitric Oxide (NO) and Suppression of Endocannabinoid Signaling |
| Q38753804 | Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in the Brain-Adipocyte Axis |
| Q37218334 | Glucagon-like peptide 1 receptor induced suppression of food intake, and body weight is mediated by central IL-1 and IL-6 |
| Q47791067 | Glucagon-like peptide-1 (GLP-1) receptor agonist prevents development of tolerance to anti-anxiety effect of ethanol and withdrawal-induced anxiety in rats |
| Q28597322 | Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria |
| Q46625008 | Glucagon-like peptide-1 prevented abdominal aortic aneurysm development in rats |
| Q50693409 | Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. |
| Q28081671 | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide |
| Q37054716 | High-fat diet changes the temporal profile of GLP-1 receptor-mediated hypophagia in rats. |
| Q38606226 | Hippocampal insulin resistance and cognitive dysfunction |
| Q36928283 | In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial |
| Q26744254 | Increasing GLP-1 Circulating Levels by Bariatric Surgery or by GLP-1 Receptor Agonists Therapy: Why Are the Clinical Consequences so Different? |
| Q34362412 | Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury |
| Q38234927 | Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia |
| Q38197368 | Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases |
| Q91592796 | Interleukin-6 in the central amygdala is bioactive and co-localised with glucagon-like peptide-1 receptor |
| Q50123735 | LC-MS/MS analysis of lipidized analogs of prolactin-releasing peptide utilizing a monolithic column and simple sample preparation. |
| Q39037677 | Lipopeptides as therapeutics: applications and in vivo quantitative analysis |
| Q58573252 | Liraglutide Activates mTORC1 Signaling and AMPA Receptors in Rat Hippocampal Neurons Under Toxic Conditions |
| Q60951190 | Liraglutide Ameliorates β-Amyloid Deposits and Secondary Damage in the Ipsilateral Thalamus and Sensory Deficits After Focal Cerebral Infarction in Rats |
| Q41090019 | Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway |
| Q90113365 | Liraglutide Protects Against Brain Amyloid-β1-42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation |
| Q46666867 | Liraglutide activates autophagy via GLP-1R to improve functional recovery after spinal cord injury |
| Q64088518 | Liraglutide and its Neuroprotective Properties-Focus on Possible Biochemical Mechanisms in Alzheimer's Disease and Cerebral Ischemic Events |
| Q92825513 | Liraglutide improves memory in obese patients with prediabetes or early type 2 diabetes: a randomized, controlled study |
| Q38775835 | Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway |
| Q47107585 | Liraglutide restores chronic ER stress, autophagy impairments and apoptotic signalling in SH-SY5Y cells |
| Q36078803 | Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer's Disease |
| Q26749191 | Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus |
| Q34202922 | Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational study |
| Q47983600 | Middle-Aged Diabetic Females and Males Present Distinct Susceptibility to Alzheimer Disease-like Pathology. |
| Q38974881 | Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology |
| Q26783344 | Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal |
| Q27005992 | Neural control of energy balance: translating circuits to therapies |
| Q30412673 | Neuronal GLP1R mediates liraglutide's anorectic but not glucose-lowering effect |
| Q90236862 | Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases |
| Q39083326 | Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress |
| Q42704044 | Neuroprotective effects of liraglutide for stroke model of rats |
| Q26866194 | New drug treatments show neuroprotective effects in Alzheimer's and Parkinson's diseases |
| Q52601566 | New views and possibilities of antidiabetic drugs in treating and/or preventing mild cognitive impairment and Alzheimer's Disease. |
| Q38668948 | Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases |
| Q51320034 | Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. |
| Q26747572 | One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug |
| Q33577712 | Optimal therapy of type 2 diabetes: a controversial challenge |
| Q98951981 | Pharmacologically reversible zonation-dependent endothelial cell transcriptomic changes with neurodegenerative disease associations in the aged brain |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q34062829 | Pleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular system |
| Q38039489 | Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection |
| Q26774021 | Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus |
| Q35589875 | Preservation of the blood brain barrier and cortical neuronal tissue by liraglutide, a long acting glucagon-like-1 analogue, after experimental traumatic brain injury |
| Q47769365 | RD Lawrence Lecture 2017 Incretins: the intelligent hormones in diabetes |
| Q64076324 | Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents |
| Q36469127 | Sex and estrogens alter the action of glucagon-like peptide-1 on reward |
| Q36994382 | Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study. |
| Q48550172 | Single dose and repeated administrations of liraglutide alter energy metabolism in the brains of young and adult rats |
| Q38713935 | Sitagliptin and liraglutide reversed nigrostriatal degeneration of rodent brain in rotenone-induced Parkinson's disease. |
| Q48321628 | Sitagliptin protects proliferation of neural progenitor cells in diabetic mice. |
| Q48379621 | Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline |
| Q38629516 | Strong Association between Plasma Dipeptidyl Peptidase-4 Activity and Impaired Cognitive Function in Elderly Population with Normal Glucose Tolerance |
| Q37729181 | Systematic Design of Trypsin Cleavage Site Mutated Exendin4-Cysteine 1, an Orally Bioavailable Glucagon-Like Peptide-1 Receptor Agonist |
| Q99561829 | Systemic and Central Amylin, Amylin Receptor Signaling, and Their Physiological and Pathophysiological Roles in Metabolism |
| Q49940117 | Tackling dipeptidyl peptidase IV in neurological disorders |
| Q36720655 | The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride |
| Q26765609 | The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity |
| Q36950218 | The Neuroprotection of Liraglutide Against Ischaemia-induced Apoptosis through the Activation of the PI3K/AKT and MAPK Pathways |
| Q47111896 | The Role of Glucagon-Like Peptide 1 (GLP1) in Type 3 Diabetes: GLP-1 Controls Insulin Resistance, Neuroinflammation and Neurogenesis in the Brain |
| Q38239573 | The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. |
| Q38779222 | The effects of hormones and physical exercise on hippocampal structural plasticity |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
| Q28598004 | The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents |
| Q33600053 | The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease |
| Q92792434 | The novel GLP-1/GIP analogue DA5-CH reduces tau phosphorylation and normalizes theta rhythm in the icv. STZ rat model of AD |
| Q52718518 | The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. |
| Q26824311 | The role of gut endocrine cells in control of metabolism and appetite |
| Q38823805 | Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia |
| Q58447447 | Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes |
| Q89819820 | Treatment With Liraglutide Exerts Neuroprotection After Hypoxic-Ischemic Brain Injury in Neonatal Rats via the PI3K/AKT/GSK3β Pathway |
| Q37516654 | Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. |
| Q57791805 | Type 2 Diabetes Mellitus and Alzheimer's Disease: Role of Insulin Signalling and Therapeutic Implications |
| Q26825253 | Type 2 diabetes and cognitive impairment: contributions from neuroimaging |
| Q64071490 | Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea |
| Q33626001 | Upper and/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences |
| Q45803529 | Val⁸-GLP-1 remodels synaptic activity and intracellular calcium homeostasis impaired by amyloid β peptide in rats |
Search more.